#Latest news with #DavidHeuzéAssociated Press10-02-2025BusinessAssociated PressCompletion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva PharmaceuticalsMONTPELLIER, France--(BUSINESS WIRE)--Feb 10, 2025-- Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE View source version on CONTACT: David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] / +33 (0)6 83 25 21 86Grace Kim Head of US Financial Strategy & IR Media Relations [email protected] / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier [email protected] / +33 (0)1 44 71 94 94 KEYWORD: FRANCE EUROPE SOURCE: Medincell Copyright Business Wire 2025. PUB: 02/10/2025 02:00 AM/DISC: 02/10/2025 02:02 AM
Associated Press10-02-2025BusinessAssociated PressCompletion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva PharmaceuticalsMONTPELLIER, France--(BUSINESS WIRE)--Feb 10, 2025-- Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE View source version on CONTACT: David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] / +33 (0)6 83 25 21 86Grace Kim Head of US Financial Strategy & IR Media Relations [email protected] / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier [email protected] / +33 (0)1 44 71 94 94 KEYWORD: FRANCE EUROPE SOURCE: Medincell Copyright Business Wire 2025. PUB: 02/10/2025 02:00 AM/DISC: 02/10/2025 02:02 AM
10-02-2025
